The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.”1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer

Androgen receptor alterations consistently emerged in serial liquid biopsies researchers used to track how metastatic prostate cancer evolves under treatment pressure. These alterations were linked to poorer outcomes across therapies, according to a multi-center collaboration of investigators from Sylvester, UC San Diego, Moores Cancer Center, the University of California, San Francisco, Scripps Research Institute, and Guardant Health. 
Clinical Roundup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects. 
Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account